Case Overview

In a significant procedural development for pharmaceutical patent litigation, the U.S. Court of Appeals for the Federal Circuit vacated and remanded a lower court’s ruling on the validity of a schizophrenia treatment patent in Sumitomo Pharma Co., Ltd. v. Slayback Pharma, LLC (Case No. 22-2276). The Federal Circuit’s decision, issued after 554 days of appellate proceedings, sends the patentability dispute back for further review — preserving Sumitomo’s position on U.S. Patent No. US9815827B2, a compound patent directed to an agent for the treatment of schizophrenia.

For pharmaceutical patent attorneys, in-house IP counsel, and R&D leaders operating in the CNS (central nervous system) drug space, this case underscores the continued volatility of invalidity challenges against branded pharmaceutical patents and the Federal Circuit’s willingness to scrutinize lower-court patentability determinations. The outcome reflects broader litigation dynamics in the ANDA (Abbreviated New Drug Application) and Hatch-Waxman ecosystem, where generic entry timelines hinge on patent validity disputes.

The Parties

The Patent at Issue

This case involved a compound patent covering an agent for the treatment of schizophrenia. The patent represents a key intellectual property asset for Sumitomo in defending market exclusivity against generic competition.

• • US9815827B2 — Compound patent for an agent for the treatment of schizophrenia
• • Application Number: US14/471919
• • Technology Area: Pharmaceutical chemistry — CNS therapeutics

The Verdict & Legal Analysis

Outcome

The Federal Circuit vacated and remanded the lower tribunal’s ruling. No damages were awarded at the appellate level, consistent with the procedural nature of a vacatur. No injunctive relief determination was made at this stage. The case is returned to the originating forum for reconsideration consistent with the appellate court’s guidance.

A vacatur-and-remand is neither a plaintiff win nor a defendant win in the conventional sense — it is a directive that the prior decision was legally flawed and must be reconsidered. For Sumitomo, this outcome preserves the validity of US9815827B2 against immediate cancellation. For Slayback, the invalidity argument remains live.

Key Legal Issues

The verdict cause is identified as patentability, with the action classified as an invalidity/cancellation challenge. This framing suggests Slayback pursued arguments that Sumitomo’s schizophrenia treatment patent failed to meet one or more statutory patentability requirements — most commonly obviousness under 35 U.S.C. § 103, anticipation under § 102, or enablement/written description under § 112 in pharmaceutical patent challenges.

The Federal Circuit’s decision to vacate — rather than affirm or reverse outright — typically signals one of several analytical failures in the lower proceeding: an erroneous claim construction standard, insufficient factual findings to support the invalidity conclusion, an improper application of the burden of proof, or a failure to adequately address secondary considerations of non-obviousness (such as long-felt need, commercial success, or unexpected results).

In pharmaceutical patent litigation, secondary considerations carry significant evidentiary weight. CNS compounds targeting conditions like schizophrenia often survive obviousness challenges when patentees can demonstrate that the claimed compound produced unexpected therapeutic results or solved a previously unmet clinical need — arguments that lower tribunals sometimes inadequately weigh.